Please login to the form below

Not currently logged in

Finland's Faron Pharmaceuticals appoints new medical director

Dr Matti Karvonen brings experience from Roche, Biogen and Novartis

Faron Pharmaceuticals Dr Matti KarvonenDr Matti Karvonen has moved from Roche to join Finland's Faron Pharmaceuticals as its new medical director.

He previously served as Roche's European medical lead and prior to that held roles with Novartis and Biogen, as well as several consultancies.

Dr Karvonen has a background in clinical neurology and in the early part of his career he held several research positions, including as research director for the University of Turku's Clinical Research Services Turku (CRST) unit.

In his new role he will join Turku-based Faron's executive management team and oversee its drug development strategy, including its clinical programmes for Traumakine and Clevegen.

Dr Markku Jalkanen, CEO of Faron, said: “We are delighted to welcome Dr Karvonen to our ambitious executive management team. His appointment comes at an important time for Faron as we expand our clinical activities.

“Our lead drug candidate Traumakine, for the treatment of Acute Respiratory Distress Syndrome (ARDS) is now in a pan-European phase III INTEREST trial, while clinical development for Clevegen, our novel cancer immunotherapy drug candidate is under active planning.”

13th May 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....